DOI QR코드

DOI QR Code

Effects of Oral Administering Kefir on Blood Glucose Levels in Diabetic Mice

Kefir의 투여가 당뇨병 마우스의 혈당치에 미치는 영향

  • Lee, Jong-Ik (Dept. of Food Science and Biotechnology of Animal Resources, College of Animal Bioscience & Technology, Konkuk University) ;
  • Song, Kwang-Young (Dept. of Public Health, College of Veterinary Medicine, Konkuk University) ;
  • Chon, Jung-Whan (Dept. of Public Health, College of Veterinary Medicine, Konkuk University) ;
  • Hyeon, Ji-Yeon (Dept. of Public Health, College of Veterinary Medicine, Konkuk University) ;
  • Kim, Hyun-Sook (Dept. of Nutrition, University of California) ;
  • Seo, Kun-Ho (Dept. of Public Health, College of Veterinary Medicine, Konkuk University)
  • 이종익 (건국대학교 동물생명과학대학 축산식품생물공학) ;
  • 송광영 (건국대학교 수의과대학 공중보건학) ;
  • 천정환 (건국대학교 수의과대학 공중보건학) ;
  • 현지연 (건국대학교 수의과대학 공중보건학) ;
  • 김현숙 (캘리포니아 대학교(UC Davis)영양학과) ;
  • 서건호 (건국대학교 수의과대학 공중보건학)
  • Received : 2011.01.28
  • Accepted : 2011.03.24
  • Published : 2011.03.30

Abstract

This study was conducted to investigate the effect of oral administering kefir on blood glucose levels in diabetic mice. Kefir($10\;m\ell/kg$ body weight) was orally administered to diabetic mice twice daily for 45 days. Diabetic mice fed saline or 10% skim milk were used as a control. No significant difference in feed intake and weight gain were observed among the treatments. Compared to the saline-fed or skim milk-fed group, blood glucose in the kefir-fed group decreased significantly at 45 days(p<0.05). At 45 days, serum triglyceride and non-esterified fatty acid concentrations in diabetic mice fed kefir decreased significantly compared to those of the saline and skim milk groups(p<0.05). Both high density lipoprotein and low density lipoprotein concentrations were not significantly different among the three treatment groups. In conclusion, the symptoms of diabetic mice improved when kefir was fed for >45 days.

본 연구에서는 당뇨병 마우스에 kefir를 투여하여 혈당과 혈액의 지질성분의 변화를 측정하여 당뇨병 치료 보조식품으로의 가능성을 규명하고자 실시하였다. 당뇨병 마우스에 kefir를 매일 2회 $10\;m\ell/kg$씩 45일간 투여하여 혈당치를 비롯하여 사료섭취율, 몸무게 변화, 혈중 지질(중성지방, 고밀도 지질단백질, 저밀도지질단백질, 유리지방산)의 함량 변화와 간의 무게를 측정하였으며, 식염수와 10% 탈지우유를 투여한 대조군과 비교하였다. 당뇨병 마우스의 체중의 변화는 처리군 간에 유의차가 없었다. 혈당의 변화는 kefir 처리군이 음성대조군인 식염수와 탈지우유처리군에 비하여 45일 후에는 혈당치가 강하되어 유의차가 있었다(p<0.05). 혈청의 지질성분 정량 결과에서 혈청중의 중성지방 함량과 유리지방산 함량은 kefir 처리군이 음성대조군인 식염수와 탈지우유 처리군과 비교하여 45일째에 유의차가 있는 감소를 보였다(p<0.05). Kefir 처리군의 고밀도지질단백질 및 저밀도지질단백질 분석치는 대조군과 유의차가 없었다. 간의 무게는 처리군 간에 차이가 거의 없었다. 본 연구의 결과를 종합하면 당뇨병 마우스에 kefir를 45일간 급여하였을 때 대조군(식염수, 탈지우유)보다 혈당치와 중성지방이 강하된 것으로 보아 kefir 투여가 당뇨병 환자에게도 기능성 보조식품으로 활용할 수 있을 것으로 사료된다.

Keywords

References

  1. Adachi S, Toba T, Arihara K. 1990. Immunofluorescence microscopic studies on distribution of Lactobacillus kefiranofaciens and Lactobacillus kefir in kefir grains. Int J Food Microbiol 11:127-134 https://doi.org/10.1016/0168-1605(90)90047-9
  2. Anderson, JW, Zergler JA, Deakins DA, Floore TL, Dillon DW, Oeltegen PR, Whitley RJ. 1991. Metabolic effects of high-carbohydrate, high-fiber diets for insulin dependent diabetes individuals. Am J Clin Nutr 54:936-943
  3. Baek YJ. 1993. Lactic acid bacteria and human health. Korean J Food & Nutr 6:53-65
  4. Batinkov, AV, Bednarz-Prashad AJ, Dupont HL, Pickering LK. 1987. Rotavirus gastroenteritis. Ann Rev Med 38:399-415 https://doi.org/10.1146/annurev.me.38.020187.002151
  5. Chen TH, Wang SY, Chen KN, Liu JR, Chen MJ. 2009. Microbiological and chemical properties of kefir manufactured by entrapped microorganisms isolated from kefir grains. J Dairy Sci 92:3002-3013 https://doi.org/10.3168/jds.2008-1669
  6. De Moreno de LeBlanc A, Matar C, Farnworth E, Perdigon G. 2007. Study of immune cells involved in the antitumor effect of kefir in a murine breast cancer model. J Dairy Sci 90:1920-1928 https://doi.org/10.3168/jds.2006-079
  7. Duitschaever CL, Kemp N, Smith AK. 1988. Microscopic studies of the microflora of kefir grains and kefir made by different methods. Milchwissensch 43:479-481
  8. Evenshtein EM. 1978. Use of kefir for stimulation of gastric secretion and acid-formation in patients with pulmonary tuberculosis. Probl Tuberk 2:82-84
  9. Hollenbeck BB, Chen YDI, Reaven GM. 1984. Comparison of the relative effects of obesity and non-insulin-dependent diabetes mellitus on in vivo insulin-stimulated glucose utilization. Diabetes 33:622-626 https://doi.org/10.2337/diab.33.7.622
  10. Kandler O, Kunath P. 1993. Lactobacillus kefir sp., component of microflora of kefir. Syst Appl Microbiol 4:286-294
  11. Kang Y, Koh YI. 1995. Induction and treatment prospective of insulin-dependent diabetes mellitus as Type 1. BiochemNet 15:388-396
  12. Kim YH, Son SP, Kang JS. 1984. Hemoglobin A1, cholesterol and triglyceride in adult onset diabetics. Kor J Intern Med 27:917-924
  13. Komai M, Nanno M. 1992. Intestinal microflora and longevity. pp. 325-353. In: Functions of Fermented Milk. Nakazawa Y, Hosono A. (eds). Elsevier Applied Science, London, UK
  14. Kourkoutas Y, Sipsas V, Papavasiliou G, Koutinas AA. 2007. An economic evaluation of freeze-dried kefir starter culture production using whey. J Dairy Sci 90:2175-2180 https://doi.org/10.3168/jds.2006-557
  15. Kwak HS, Park SK, Kim DS. 1996. Biostabilization of kefir with a nonlactose-fermenting yeast. J Dairy Sci 79:937-942 https://doi.org/10.3168/jds.S0022-0302(96)76444-5
  16. Kwon CS, Park MY, Cho JS, Choi ST, Chang DS. 2003. Identification of effective microorganisms from kefir fermented milk. Food Sci Biotechnol 12:476-479
  17. Lee HJ, Nam BR, Kim JM, Kim JY, Paik HD, Kim CH. 2007. Antitumor effects of Kluyveromyces marxianus TFM-7 isolated from kefir. Food Sci Biotechnol 16:133-137
  18. Lee JI, Song KY, Chon JW, Hyeon JY, Seo KH. 2010. Physicochemical properties of kefir as dietary supplementary for curing the diabetic mouse. Korean J Food & Nutr 23:462-469
  19. Nakajima H, Toyoda S, Toba T, Itoh T, Mukai T, Kitazawa H, Adachi S. 1990. A novel phosphopolysaccharide from slimforming Lactococcus lactis subspecies cremoris SBT 0495. J Dairy Sci 73:1472-1477 https://doi.org/10.3168/jds.S0022-0302(90)78812-1
  20. Oda M, Hasegawa H, Komatsu S, Kambem K, Tsuchiya F. 1983. Antitumor polysaccharide from Lactobacillus sp. Agric Biol Chem 47:1623-1625 https://doi.org/10.1080/00021369.1983.10865826
  21. Otle S, Cagindi O. 2003. Kefir: A probiotic dairy-compostion, nutritional and therapeutic aspects. Park J Nutr 2:54-59
  22. Ottogalli G, Galli A, Resmini P, Volonterio G. 1973. Microbiological and chemical composition ultrastructure of kefir grains. Ann Microbiol Enzim 23:109-121
  23. Quiros A, Hernandez-Ledesma B, Ramos M, Amigo L, Reclo I. 2005. Angiotension-converting enzyme inhibitory activity of peptides derived from caprine kefir. J Dairy Sci 88:3480-3487 https://doi.org/10.3168/jds.S0022-0302(05)73032-0
  24. Shiomi M, Sasaki K, Murofushi M, Aibara K. 1982. Antitumor activity in mice of orally administered polysaccharide from kefir grain. Jap J Med Sci Biol 35:75-80 https://doi.org/10.7883/yoken1952.35.75
  25. Toba T, Uemura H, Mukai T, Itoh T, Adachi S. 1991. A new fermented milk using capsular polysaccharide-producing Lactobacillus kefiranofaciens isolated from kefir grains. J Dairy Res 58:497-502 https://doi.org/10.1017/S0022029900030107
  26. Umeda C, Sonoyama K, Yamaguchi N, Saito R, Akashi K, Motoshima H, Kawabata J. 2005. Oral administration of freeze-dried kefir reduces intestinal permeation of and oral sensitization to ovalbumin in mice. Biosci Biotech Biochem 69:249-251 https://doi.org/10.1271/bbb.69.249
  27. Wszolek M, Tamime AY, Muir DD, Barclay NI. 2001. Properties of kefir made in Scotland and Poland using bovine, caprine, and ovine milk with different starter cultures. Lebensm Wiss Technol 34:251-261 https://doi.org/10.1006/fstl.2001.0773
  28. Yoon YH, Kang DG, Baek YJ, Huh CS. 1998. Cholesterol assimilation activity of Lactobacillus spp. from kefir and yoghurt and non starter strains. Kor J Dairy Sci 20:143-152

Cited by

  1. Anti-Diabetic Studies of Mass Cultured Mycelia from Ganoderma applanatum in db/db Mice and Human vol.26, pp.3, 2013, https://doi.org/10.9799/ksfan.2013.26.3.366
  2. Milk kefir: nutritional, microbiological and health benefits vol.30, pp.01, 2017, https://doi.org/10.1017/S0954422416000275